M
Moreno Di Marco
Researcher at University of Tübingen
Publications - 15
Citations - 343
Moreno Di Marco is an academic researcher from University of Tübingen. The author has contributed to research in topics: Human leukocyte antigen & MHC class I. The author has an hindex of 9, co-authored 15 publications receiving 196 citations.
Papers
More filters
Journal ArticleDOI
Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices.
Moreno Di Marco,Heiko Schuster,Linus Backert,Michael Ghosh,Hans-Georg Rammensee,Stefan Stevanovic +5 more
TL;DR: This study elucidated the peptide specificities of these HLA molecules using a comprehensive analysis of naturally presented peptides and validated the wealth of HLA ligands resulted in prediction matrices for octa-, nona-, and decamers.
Journal ArticleDOI
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich,Quinlen F. Marshall,John M. Warrington,Rasika Premaratne,Alvin Farrel,David Groff,Wei Li,Moreno Di Marco,Erin Runbeck,Hau Truong,Jugmohit S. Toor,Sarvind Tripathi,Son Nguyen,Helena Shen,Tiffany Noel,Nicole L. Church,Amber K. Weiner,Nathan M. Kendsersky,Daniel Martinez,Rebecca Weisberg,Molly Christie,Laurence C. Eisenlohr,Kristopher R. Bosse,Kristopher R. Bosse,Dimiter S. Dimitrov,Stefan Stevanovic,Nikolaos G. Sgourakis,Ben R. Kiefel,John M. Maris,John M. Maris +29 more
TL;DR: In this article, a peptide-centric chimeric antigen receptor (CAR) was proposed to target unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B.
Journal ArticleDOI
Excreted Cytoplasmic Proteins Contribute to Pathogenicity in Staphylococcus aureus
Patrick Ebner,Janina Rinker,Minh-Thu Nguyen,Peter Popella,Mulugeta Nega,Arif Luqman,Birgit Schittek,Moreno Di Marco,Stefan Stevanovic,Friedrich Götz +9 more
TL;DR: The impact of two excreted glycolytic enzymes, aldolase (FbaA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), on pathogenicity was investigated in Staphylococcus aureus and the contribution of external FbaA and GAPDH was confirmed in an insect infection model.
Journal ArticleDOI
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
Hans-Georg Rammensee,Hans-Georg Rammensee,Karl Heinz Wiesmüller,P. Anoop Chandran,Henning Zelba,Elisa Rusch,Cécile Gouttefangeas,Cécile Gouttefangeas,Daniel J. Kowalewski,Moreno Di Marco,Sebastian P. Haen,Sebastian P. Haen,Juliane S. Walz,Yamel Cardona Gloria,Johanna Bödder,Jill Marie Schertel,Antje Tunger,Antje Tunger,Luise K. Müller,Maximilian Kießler,Rebekka Wehner,Rebekka Wehner,Rebekka Wehner,Marc Schmitz,Marc Schmitz,Marc Schmitz,Meike Jakobi,Nicole Schneiderhan-Marra,Reinhild Klein,Karoline Laske,Kerstin Artzner,Linus Backert,Heiko Schuster,Johannes Schwenck,Alexander N.R. Weber,Bernd J. Pichler,Manfred Kneilling,Christian la Fougère,Christian la Fougère,Stephan Forchhammer,Gisela Metzler,Jürgen Bauer,Benjamin Weide,Wilfried Schippert,Stefan Stevanovic,Stefan Stevanovic,Markus W. Löffler +46 more
TL;DR: A granuloma forming by peptides combined with an efficient adjuvant in a water-in-oil-emulsion, inducing antigen specific T cells detectable in circulation and at the vaccination site, after one single vaccination only is shown.
Journal ArticleDOI
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Anna Reustle,Anna Reustle,Moreno Di Marco,Carolin Meyerhoff,Carolin Meyerhoff,Annika Nelde,Juliane S. Walz,Stefan Winter,Stefan Winter,Siahei Kandabarau,Siahei Kandabarau,Florian Büttner,Florian Büttner,Mathias Haag,Mathias Haag,Linus Backert,Daniel J. Kowalewski,Steffen Rausch,Jörg Hennenlotter,Viktoria Stühler,Marcus Scharpf,Falko Fend,Arnulf Stenzl,Hans-Georg Rammensee,Jens Bedke,Stefan Stevanovic,Matthias Schwab,Elke Schaeffeler,Elke Schaeffeler +28 more
TL;DR: In this paper, the authors developed a workflow integrating different -omics technologies to identify ccRCC-specific HLA-presented peptides as potential drug targets for CCRCC immunotherapy.